Lawsuit is part of a nationwide strategy by Novo Nordisk to protect its trademark and profits from its blockbuster GLP-1 ...

The Northeast Microelectronics Coalition Hub announced on Wednesday that it had been awarded $37.8 million in federal ...

In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.

“These are scams,” said Kenny Biddle, the chief investigator for the Center of Inquiry, an organization devoted to defending ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

NanoVation Therapeutics partners with Novo Nordisk to develop genetic medicines for cardiometabolic and rare diseases, utilizing NanoVation's lipid nanoparticle technology. The deal includes research ...

Shutterstock / Caroline Ruda In 2022, the FDA placed tirzepatide — the active ingredient in Eli Lilly’s Mounjaro and Zepbound ...

Ozempic is not approved for use in weight loss, however, many people have been taking the drug for this purpose. Semaglutide was approved for weight loss purposes under another name—Wegovy—which has a ...

Hennepin County Board approved a 5.5% increase to the 2025 property tax levy, which will raise more than $1 billion in ...

Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...

Theratechnologies’ supply hiccup is the second caused by third-party manufacturing problems in less than a week. On Friday, ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.